Yaron Pereg

Company: KAHR Bio

Job title: Chief Executive Officer

Seminars:

DSP107, a Novel CD47x4-1BB targeting agent 1:30 pm

Virtual Presentation Improving Target Specificity and Activity Through the Use of Bispecific Fusion Protein Designing bispecific agent to successfully mediate dual activation of innate and adaptive immune systems Transforming safety profile and avoiding hematological toxicities Enhancing the potential for the treatment of solid and hematological malignancies Read more

day: Day One Track B PM